Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.
EMBARGO 31 August 2015 at 08:00 BST
STUDY NAME: The ELIXA Trial
SESSION NAME: Hot Line III - Diabetes Mellitus/Pharmacology
The study, presented today at ESC Congress 2015, “demonstrates the cardiovascular safety of lixisenatide”, reported Eldrin F. Lewis, MD, MPH, a member of the ELIXA trial’s executive committee, a physician in the Cardiovascular Medicine Division at Brigham and Women’s Hospital and an associate professor at Harvard Medical School, in Boston, USA.
The results of the ELIXA trial, originally presented in June at the American Diabetes Association, are the first to be reported on the CV safety outcomes of a glucagon-like peptide 1 (GLP-1) receptor agonist.
“Prior studies have established that patients with type 2 diabetes are at higher risk for incident cardiovascular disease than people who do not have type 2 diabetes, and some glucose-lowering drugs have been associated with increased risk of cardiovascular disease,” said Dr. Lewis, explaining that this has prompted both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) and to establish guidelines for clinical trials that would ensure cardiovascular safety in glucose-lowering therapies.
The ELIXA trial was powered to establish safety (non-inferiority) and superiority of lixisendatide versus placebo. Although it was not able to establish the superiority of lixisenatide over placebo for CV safety, “the neutral effects on cardiovascular events are all within the limits of the EMA’s and FDA’s guidelines,” commented Dr. Lewis. “In addition, lixisenatide provided a modest benefit in terms of weight gain.”
The study included 6,068 patients (mean age 60.3 years) with type 2 diabetes and a history of myocardial infarction (83%) or hospitalisation for unstable angina (17%) within the past 180 days.
The patients were randomised to receive daily injections of either lixisenatide or placebo and followed for a minimum of 10 months to measure the primary outcome: a composite of cardiovascular death, heart attacks, stroke, and hospitalisation for unstable angina. Important additional outcome measures included all-cause death and heart failure hospitalisations.
This outcome occurred in 13.4 percent of the lixisenatide group compared to 13.2 percent of the placebo group, with the hazard ratio of 1.02 and a 95% confidence interval that was “well below the standard set by the FDA,” noted Dr. Lewis.
Lixisenatide was also safe in patients with a history of heart failure. Among patients with a history of chronic heart failure prior to randomisation, approximately 10% had a hospitalisation for heart failure during follow-up, compared to 2.4% of patients without a history of chronic heart failure.
“The hazard ratio was similar between lixisenatide and placebo demonstrating similar CV safety of lixisenatide in this population,” he said.
However, patients who were hospitalised for heart failure had a risk of all-cause death that was 9-fold greater than those who were not hospitalised for heart failure. “This excess mortality suggests that these are important events to capture among patients with diabetes,” said Dr. Lewis.
SOURCES OF FUNDING: The study was funded by Sanofi.
DISCLOSURES: The authors received funding from Sanofi to conduct the study.
ESC Press OfficeFor background information, please contact the ESC Press Office.For independent comment on site, please contact the ESC Spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
© 2017 European Society of Cardiology. All rights reserved